Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)

Ran Jin; Adesuwa S Ogbomo; Neil A Accortt; Lincy S Lal; Geetanjali Bishi; Darcie Sandschafer; Jerome H Goldschmidt

doi:10.1177/17588359231182386

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)

Ther Adv Med Oncol. 2023 Jun 21:15:17588359231182386. doi: 10.1177/17588359231182386. eCollection 2023.

Authors

Ran Jin¹, Adesuwa S Ogbomo², Neil A Accortt³, Lincy S Lal², Geetanjali Bishi², Darcie Sandschafer³, Jerome H Goldschmidt⁴

Affiliations

¹ Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.
² ConcertAI, Cambridge, MA, USA.
³ Amgen Inc., Thousand Oaks, CA, USA.
⁴ Blue Ridge Cancer Care, Blacksburg, VA, USA.

Abstract

Background: Bevacizumab-awwb (MVASI^®) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin^® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation.

Objectives: Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP).

Design: A retrospective chart review study.

Methods: Adult patients who had a confirmed diagnosis of mCRC (initial presentation of CRC on or after 01 January 2018) and initiated 1L bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified from the ConcertAI Oncology Dataset. A chart review was conducted to evaluate patient baseline clinical characteristics and effectiveness and tolerability outcomes during the follow-up. Study measures were reported stratified by prior use of RP: (1) naïve patients and (2) switchers (patients who switched to bevacizumab-awwb from RP without advancing the line of therapy).

Results: At the end of study period, naïve patients (n = 129) had a median 1L progression-free survival (PFS) of 8.6 months [95% confidence interval (CI), 7.6-9.9] and a 12-month overall survival (OS) probability of 71.4% (95% CI, 61.0-79.5%). Switchers (n = 105) had a median 1L PFS of 14.1 months (95% CI, 12.1-15.8) and a 12-month OS probability of 87.6% (95% CI, 79.1-92.8%). During treatment with bevacizumab-awwb, 20 events of interest (EOIs) were reported in 18 naïve patients (14.0%) and 4 EOIs reported in 4 switchers (3.8%), of which the most commonly reported events were thromboembolic and hemorrhagic events. Most EOIs resulted in emergency department visit and/or treatment hold/discontinuation/switch. None of the EOIs resulted in death.

Conclusion: In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.

Keywords: bevacizumab; bevacizumab-awwb; biosimilar; metastatic colorectal cancer; real-world outcomes.